Advancing Medical Breakthroughs with Nanotechnology Solutions
POP Biotechnologies develops platform technologies addressing critical needs in oncology and infectious disease.
Our Expertise
The Power of PoP
POP BIO uses two patented porphyrin-phospholipid (PoP) liposome technologies to create nanomedicines to address needs in immuno-oncology and infectious disease.
Accelerated Vaccine Development
The Spontaneous Nanoliposome Antigen Particleization (POP BIO SNAP) platform enables the rapid development of highly immunogenic vaccines
Targeted Chemotherapy
Chemophototherapy (CPT) using PoP liposomes to deliver targeted concentrations of chemotherapy drugs to tumors expose to specific laser light.
Latest News
POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy
September 13, 2024
POP Biotechnologies has announced positive results for their pentavalent peptide vaccine targeting Alzheimer’s Disease, published in Brain Behavior and Immunity. The vaccine, utilizing POP BIO’s SNAP™ technology, demonstrated efficacy in mice by targeting multiple epitopes of amyloid-β and tau proteins, showing potential for treating early-stage AD. The vaccine is now advancing toward clinical trials through EuPOP Life Sciences, a joint venture with EuBiologics.
POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy
August 21, 2024
POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out.
POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials
August 7, 2024
POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea
Discover Our Exciting Clinical Developments
Stay updated with our latest projects and collaborations in the field of biotechnology.
We are Actively Expanding Our Strong IP Protection
Exclusive license from SUNY for entire POP BIO SNAP and related patent portfolio
Formulations for MHC-I Restricted Epitope Immunization
Priority 1/2021
PCT WO2022155156
Particle based formulations of SAR-CoV-2 receptor binding domain
Priority 9/2020
PCT WO2022072654A1
Continuation In Part of above with examples in RSV, Influenza, and Lyme antigens
Priority 8/2019
U.S.A US20190255188
PCT WO2022072654A1
Serum-stable Compositions and Methods for Light Triggered Release of Materials
Priority 9/2015
European Union
Designated:
Belgium, France, Germany, United Kingdom,Italy, Ireland, Netherlands, Spain, Sweden, Switzerland EP3277264
Belgium, France, Germany, United Kingdom,Italy, Ireland, Netherlands, Spain, Sweden, Switzerland EP3277264
Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
Priority 4/2015
Australia AU2016248454
Canada CA2981359
China CN107708671
India 201717037629
Japan JP2018513156
U.S.A. US10,272,160
European Union
Belgium 167809961
France WO2020223395
Germany CA000002981359A1
United Kingdom EP16780996
Italy 502021000020480
Ireland 3283056
Netherlands EP3283056
Spain ES2865392
Sweden EP16780996.1
Switzerland 16780996
Compositions and Method for Light Triggered Release of Materials from Nanovesicles
Priority 12/2012
European Union